Y-mAbs Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: YMAB
SEC CIK: 0001722964
Phone: 212-847-9841
230 PARK AVENUE
SUITE 3350
NEW YORK NY 10169
CEO:
|
Price when page updated: 5.99 Date: 2023-12-02
Company Website:
www.ymabs.com
|
_Description: Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
IPO YEAR:
2018
|
Sector:
Health Care
|
Industry:
Biotechnology: Pharmaceutical Preparations
|
ADRTSO:
|
MarketCap:
261293492.00
|
Beta:
1.357638610900444
|
52 Week High:
53.18
|
52 Week Low:
14.95
|
52 Week Change:
-0.6619075946857029
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
43643916
|
Dividend Rate:
0
|
Dividend Yield:
0.00%
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
22 Nov 2022
|
Float:
0
|
return on Equity:
18.10%
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
N/A
|
ttmEPS:
0
|
Revenue:
¥3.500B
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
1.10%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
-
|
Return on Assets:
9.40%
|
Return on Capital:
|
Profit Margin:
21.00%
|
Price to Sales:
0.19
|
Price To Book:
0.16
|
Short Ratio:
1.87
|
PE Ratio:
0
|
Employees:
125
|
1Y Guesstimate
N/A:N/A:N/A
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__Y-mAbs Therapeutics Inc. Common Stock [ YMAB ].
__Note: Some Links might not have information for the company.
|
|
